Fierce Pharma
Safety of muscular dystrophy gene therapy in spotlight after two deaths connected to Novartis Zolgensma treatments
Novartis has recorded two deaths after treatment with its spinal muscular atrophy gene therapy Zolgensma, once again bringing gene therapy’s ...
